冰山冷熱(000530.SZ):擬4540萬元受讓中慧達所持華慧達20%股權
格隆匯3月19日丨冰山冷熱(000530.SZ)公佈,大連冰山集團華慧達融資租賃有限公司(“華慧達”)由大連中慧達製冷技術有限公司(“中慧達”)和大連冰山集團管理諮詢有限公司(“冰山諮詢”)、東京盛世利株式會社(“盛世利”)共同出資設立。華慧達註冊資本為人民幣1.7億元,中慧達持有其20%股權,冰山諮詢持有其40%股權,盛世利持有其40%股權。
為強化冷熱產業鏈融資、助推銷售及回收,公司擬與中慧達簽署《股權轉讓合同》,受讓中慧達所持華慧達20%股權,受讓價格為4540萬元。由於公司董事同時擔任中慧達董事,中慧達為公司的關聯法人,該次交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.